个人简介

Charles W. Flexner, M.D., is Professor of Medicine in the Divisions of Clinical Pharmacology and Infectious Diseases, and Professor of Pharmacology and Molecular Sciences in the Johns Hopkins University School of Medicine. He is also Professor of International Health in the Johns Hopkins University Bloomberg School of Public Health. Dr. Flexner is an expert on the basic and clinical pharmacology of drugs for HIV/AIDS and related infections, including viral hepatitis and tuberculosis. His scientific contributions include work on the important roles of pharmacokinetic enhancement, adherence, and dosing frequency in the long-term management of HIV/AIDS. He has published extensively on anti-infective drug transport and metabolism, and metabolic drug interactions. Dr. Flexner is currently the Deputy Director of the Institute for Clinical and Translational Research at Johns Hopkins, where he serves as Program Director for Clinical Research Units. He also serves as Associate Vice-Chair for Academic Fellowship Programs in the Department of Medicine, and Associate Director of the Graduate Training Programs in Clinical Investigation of the Johns Hopkins University School of Medicine and Bloomberg School of Public Health. Dr. Flexner is the Principal Investigator of the Johns Hopkins University AIDS Clinical Trials Unit (ACTU) supported by the NIH, and was Chair of the AIDS Clinical Trials Group (ACTG) Translational Research and Drug Development (TRADD) Committee from 2009-2011. Dr. Flexner served as President of the American Federation for Medical Research (AFMR) in 1999-2000, and was President of the AFMR Foundation from 2001-2002. He is a member of the editorial board of 10 scientific journals. He currently serves as a consultant to the Bill and Melinda Gates Foundation and the Clinton Health Access Initiative, and served as a consultant on FDA reform to the United States House of Representatives. MD, Johns Hopkins University School of Medicine (1982)

研究领域

Clinical Pharmacology; Antiviral chemotherapy; HIV protease inhibitors and entry inhibitors; Basic and clinical pharmacology of antiretroviral drugs

Clinical research activities investigate the clinical pharmacology of new anti-HIV therapies and drug combinations. Specific drug classes studied include HIV reverse transcriptase inhibitors, protease inhibitors, entry inhibitors (selective CCR5 and CXCR4 antagonists), and integrase inhibitors. Scientific objectives of clinical studies include characterization of early drug activity, toxicity, and pharmacokinetics. Additional objectives are characterization of pathways of drug metabolism, and identification of clinically significant harmful and beneficial drug interactions mediated by hepatic and intestinal cytochrome P450 isoforms.

近期论文

查看导师最新文章 （温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, Smith K, Lisziewicz J, Lori F, Flexner C, Quinn TC, Chaisson RE, Rosenberg E, Walker B, Gange S, Gallant J, Siliciano RF. 1999. Latentinfection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nature Med 5:512-517. Hendrix CW, Flexner C, MacFarland RT, Fuchs EJ, Redpath E, Bridger G, Henson GW. 2000. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother 44: 1667-1673. Speck RS, Flexner C, Tian C-J, Yu X-F. 2000. Comparison of human immunodeficiency virus type 1 Pr55Gag and Pr160Gag-Pol processing intermediates that accumulate in primary and transformed cells treated with peptidic and non-peptidic protease inhibitors. Antimicrob Agents Chemother 44: 1397-1403. Speck RR, Yu X-F, Hildreth, JE, Flexner C. 2002. Differential effects of P-glycoprotein and multidrug resistance protein-1 on productive HIV infection. J Infect Dis 186: 332-340. Nettles RE, Kieffer TL, Parsons T, Johnson J, Cofrancesco J, Gallant JE, , Carson K, Siliciano RF, Flexner C. Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring. Clin Infect Dis 2006; 42: 1189-1196. Flexner C. HIV drug development: the next 25 years. (Invited review). Nature Reviews Drug Discovery 2007; 6: 959-966. Crawford KW, Li C, Keung A, Su Z, Hughes MD, Greaves W, Kuritzkes D, Gulick R, Flexner C, for the ACTG A5211 Study Team. Pharmacokinetic/ pharmacodynamic modeling of the antiretroviral activity of the CCR5 antagonist vicriviroc in treatment-experienced HIV-infected patients. J Acq Immunodef Syndr 2010; 53: 598–605. Crawford KW, Spritzler J, Kalayjian R, Parsons T, Landay A, Pollard R, Stoker V, Lederman M, Flexner C. Age-related changes in the plasma concentrations of the HIV protease inhibitor lopinavir. AIDS Res Hum Retroviruses 2010; 26: 635-643. Flexner C, Tierney C, Gross R, Andrade A, Lalama C, Eshleman SH, Aberg J, Sanne I, Parsons T, Kashuba A, Rosenkranz SL, Kmack A, Ferguson E, Dehlinger M, Mildvan D, AIDS Clinical Trials Group A5073 Study Team. Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naïve patients: results of AIDS Clinical Trials Group (ACTG) A5073, a 48-week randomized controlled trial. Clin Infect Dis 2010; 50:1041–1052. [PMCID #2833234] Chen J, Garner RC, Lee LS, Seymour M, Fuchs EJ, Hubbard W, Parsons T, Pakes GE, Fletcher CV, Flexner C. Accelerator mass spectrometry measurement of intracellular concentrations of active drug metabolites in human target cells in vivo. Clin Pharmacol Ther 2010; 88: 796-800. Swindells S, Flexner C, Fletcher CV, Jacobson JM. The critical need for alternative antiretroviral formulations and obstacles to their development. J Infect Dis 2011; 204: 669-674. Wang L, Soon GH, Seng K-Y, Li J, Lee E, Yong E-L, Goh B-C, Flexner C, Lee L. Pharmacokinetic modeling of plasma and intracellular concentrations of raltegravir in healthy volunteers. Antimicrob Agents Chemother 2011; 55: 4090-4095. Crawford KW, Ripin DHB, Levin AD, Campbell JR, Flexner C. Optimizing the manufacturing, formulation, and dosage of antiretroviral drugs for more cost-efficient delivery in resource-limited settings: a consensus statement. Lancet Infect Dis 2012; 12: 550–60. Chen J, Flexner C, Liberman RG, Skipper PL, Louissaint N, Tannenbaum SR, Hendrix CW, Fuchs EJ. Biphasic elimination of tenofovir diphosphate and nonlinear pharmacokinetics of zidovudine triphosphate in a microdosing study. J Acq Immunodef Syndr 2012; 61: 593-599. Williams J, Sayles HR, Meza JL, Sayre P, Sandkovsky U, Gendelman HE, Flexner C, Swindells S. Long-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients. Nanomedicine (Lond). 2013; 8: 1807-1813.